Cleerly LABS vs ElucidVivo A.3

When choosing between Cleerly LABS and ElucidVivo A.3, physicians should consider their primary focus in cardiovascular imaging analysis. Both are FDA-cleared AI tools for analyzing CT angiography, but they offer distinct strengths. Cleerly LABS excels in comprehensive coronary plaque assessment, providing detailed quantification of plaque volume and type, stenosis detection, and even ischemia detection with its ISCHEMIA module. It’s designed for personalized heart disease risk assessment and tracking disease progression over time, making it suitable for long-term management and preventative cardiology.

ElucidVivo A.3, on the other hand, specializes in the quantitative analysis of arterial plaque composition and stability, with a unique focus on objectively quantifying specific plaque components like Lipid-Rich Necrotic Core (LRNC), matrix, and calcifications. Its key practical difference lies in its validation against histology and its ability to derive fractional flow reserve (FFRct) based on vessel wall vasodilative capacity. This makes ElucidVivo A.3 particularly valuable for stratifying patients with atherosclerosis and optimizing treatment decisions based on plaque vulnerability.

Therefore, a physician prioritizing a broad, longitudinal view of coronary atherosclerosis and overall heart disease risk management might favor Cleerly LABS. Conversely, a physician focused on detailed plaque characterization, stability assessment, and treatment optimization for specific atherosclerotic lesions, especially in vascular surgery or interventional cardiology, would likely find ElucidVivo A.3 more aligned with their needs.

Reviewed by Pouyan Golshani, MD — Interventional Radiologist